A detailed history of Balasa Dinverno & Foltz LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Balasa Dinverno & Foltz LLC holds 3,169 shares of NVO stock, worth $336,325. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,169
Previous 3,139 0.96%
Holding current value
$336,325
Previous $350,000 9.71%
% of portfolio
0.02%
Previous 0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022

BUY
$95.28 - $116.93 $2,858 - $3,507
30 Added 0.96%
3,169 $316,000
Q2 2022

Aug 09, 2022

BUY
$103.24 - $121.81 $2,993 - $3,532
29 Added 0.93%
3,139 $350,000
Q1 2022

Apr 25, 2022

SELL
$93.1 - $112.54 $5,865 - $7,090
-63 Reduced 1.99%
3,110 $345,000
Q4 2021

Jan 26, 2022

BUY
$95.88 - $117.08 $6,040 - $7,376
63 Added 2.03%
3,173 $355,000
Q3 2021

Oct 26, 2021

BUY
$84.42 - $106.62 $9,201 - $11,621
109 Added 3.63%
3,110 $299,000
Q2 2021

Jul 23, 2021

BUY
$67.66 - $84.76 $203,047 - $254,364
3,001 New
3,001 $251,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $240B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Balasa Dinverno & Foltz LLC Portfolio

Follow Balasa Dinverno & Foltz LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balasa Dinverno & Foltz LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balasa Dinverno & Foltz LLC with notifications on news.